Tuberous sclerosis cost-effectiveness of therapy: Difference between revisions
Jose Loyola (talk | contribs) No edit summary |
Jose Loyola (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tuberous sclerosis}} | {{Tuberous sclerosis}} | ||
{{CMG}} | {{CMG}} {{AE}} {{Jose}} | ||
== Overview == | == Overview == | ||
Latest revision as of 17:58, 23 June 2020
|
Tuberous sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberous sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tuberous sclerosis cost-effectiveness of therapy |
|
Tuberous sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Tuberous sclerosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
The treatment of tuberous sclerosis can be expensive, especially considering that many complications have surgical options for treatment.
Cost-effectiveness of Therapy
A study from 2016 showed that for children with TSC presenting with refractory epilepsy (defined by the persistence of seizures despite the use of 2 anti-seizure drugs), the most cost-effective measure between resective epilepsy surgery, vagus nerve stimulator implantation, ketogenic diet, and addition of a third anti-seizure drug, was the addition of a third drug into the medication regimen,[1]
References
- ↑ Fallah, Aria, et al. "Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex." Epilepsy & Behavior 63 (2016): 79-88.